P. Bataille et al., Renal and hypertensive complications of extracorporeal shock wave lithotripsy: Who is at risk?, UROL INTERN, 62(4), 1999, pp. 195-200
Extracorporeal shock wave lithotripsy (ESWL.) is now used in the treatment
of about 90% of renal and ureteral stones. Because of the nonpunctual deliv
ery of energy to the stone, a small volume of renal parenchyma is injured g
iving place to a fibrous scar which can be shown by highly resolutive imagi
ng techniques like magnetic nuclear resonance. Isotopic clearances point to
a reduction of 15% in the renal plasma flow on the side of the lithotripsy
, but this alteration appears to be transient in nature. In a few cases an
abrupt onset of transient hypertension has been reported in clear relation
to a compressive perirenal hematoma. The responsibility of ESWL in the late
occurrence of permanent hypertension is, however, still uncertain, probabl
y because of the difficulty in showing that this occurrence is not only rel
ated to the older age of the patient. The American Food and Drug Administra
tion-sponsored multicentric study begun in 1992 should solve this issue in
the future. Recent articles suggest that altered renal function prior to ES
WL would predict the late occurrence of hypertension and worsening of renal
failure. Furthermore, age and the resistance index of arcuate or interloba
r renal arteries (measured by Doppler) could help to screen patients at ris
k of developing hypertension. In practice in patients over 60 years of age
and/or with a plasma creatinine of >to 300 mu mol/l, ESWL should be perform
ed with caution, and renal function and blood pressure should be carefully
monitored. Copyright (C) 1999 S. Karger AG, Basel.